Search results for "PHARMACOKINETICS"

showing 10 items of 458 documents

In vitro evaluation of poloxamer in situ forming gels for bedaquiline fumarate salt and pharmacokinetics following intramuscular injection in rats

2019

Graphical abstract

In situPO Propylene oxideIV IntravenousP338 Poloxamer 338lcsh:RS1-441Pharmaceutical Sciencechemistry.chemical_compoundn Sample sizeSD Standard deviationIM Intramuscularchemistry.chemical_classificationC0 Analyte plasma concentration at time zeroDoE Design of experimentsUV UltravioletPharmacology. TherapyK2.EDTA Potassium ethylenediaminetetraacetic acidLC–MS/MS Liquid chromatography-tandem mass spectrometryH&E Hematoxylin and eosintmax Sampling time to reach the maximum observed analyte plasma concentrationIn situ forming gelsCMC Critical micellar concentrationCmax Maximum observed analyte plasma concentrationIntramuscular injectionDN Dose normalizedGPT Gel point temperaturePLGA Poly-(DL-lactic-co-glycolic acid)TFA Trifluoroacetic acidCAN AcetonitrileATP Adenosine 5′ triphosphateSalt (chemistry)Polyethylene glycolPoloxamerArticlelcsh:Pharmacy and materia medicaPharmacokineticsIn vivoUHPLC Ultra-high performance liquid chromatographyPharmacokineticsAUClast Area under the analyte concentration versus time curve from time zero to the time of the last measurable (non-below quantification level) concentrationEO Ethylene oxideNMP N-methyl-2-pyrrolidoneComputingMethodologies_COMPUTERGRAPHICSAUC∞ Area under the analyte concentration vs time curve from time zero to infinite timeP407 Poloxamer 407In vitro releasePoloxamerCMT Critical micellar temperatureGel erosionIn vitrot1/2 Apparent terminal elimination half-lifechemistryMDR-TB Multi-drug resistant tuberculosisAUC80h Area under the analyte concentration versus time curve from time zero to 80 htlast Sampling time until the last measurable (non-below quantification level) analyte plasma concentrationMRM Multiple reaction monitoringNuclear chemistrySustained releaseInternational Journal of Pharmaceutics: X
researchProduct

Exact algorithms for the multi-compartment vehicle routing problem with flexible compartment sizes

2021

Abstract The multi-compartment vehicle routing problem with flexible compartment sizes is a variant of the classical vehicle routing problem in which customers demand different product types and the vehicle capacity can be separated into different compartments each dedicated to a specific product type. The size of each compartment is not fixed beforehand but the number of compartments is limited. We consider two variants for dividing the vehicle capacity: On the one hand the vehicle capacity can be discretely divided into compartments and on the other hand compartment sizes can be divided continuously. The objective is to minimize the total distance of all vehicle routes such that all custo…

Information Systems and ManagementGeneral Computer ScienceComputer scienceModeling and SimulationVehicle routing problemManagement Science and Operations ResearchRouting (electronic design automation)Compartment (pharmacokinetics)AlgorithmIndustrial and Manufacturing EngineeringEuropean Journal of Operational Research
researchProduct

Josamycin Concentration in Human Ejaculate and its Influence on Sperm Motility/Josamycinkonzentrationsbestimmung in menschlichem Ejakulat und deren E…

2009

The concentration of josamycin was determined in the split ejaculate of 5 volunteers after oral administration for several days. One aim of this investigation was to examine the penetration of the macrolide antibiotic into the prostate and the seminal vesicles. 2.23 +/- 1.8 micrograms/ml josamycin was found in fraction I of the ejaculate, consisting mostly of prostatic secretion, and 1.56 +/- 1.37 micrograms/ml josamycin in fraction II comprising mainly secretions from the seminal vesicles. The concentrations of josamycin found in both fractions of the ejaculate are clearly comparable with serum levels of the antibiotic. Josamycin thus attains concentrations in the prostate and seminal vesi…

Josamycinbusiness.industrymedicine.drug_classGenitourinary systemUrologyAntibioticsSemenGeneral MedicineAndrologyEndocrinologymedicine.anatomical_structurePharmacokineticsOral administrationProstateImmunologyMedicinebusinessSperm motilitymedicine.drugAndrologia
researchProduct

Renal and nonrenal clearances of ceftriaxone at the steady-state and its relation to plasma protein binding

1995

Abstract The effect of the saturable plasma protein binding of ceftriaxone on the elimination of this drug was studied under steady-state conditions in the rat. A concentration-dependent increase in the total, renal and nonrenal clearances of total drug (bound + unbound) was observed, and it was related to the increase in the ex vivo unbound fraction of ceftriaxone as the plasma concentration increased. The nonrenal clearance of the unbound ceftriaxone showed a statistically significant decrease as the plasma concentration of the unbound drug at the steady state increased, which indicates that the nonrenal elimination of the drug (mainly by biliary excretion) is a saturable process. Renal c…

Kidneymedicine.medical_specialtyChemistryPharmaceutical ScienceRenal functionmedicine.anatomical_structureEndocrinologyPharmacokineticsRenal physiologyInternal medicineBlood plasmamedicineCeftriaxoneSteady state (chemistry)medicine.drugAntibacterial agentEuropean Journal of Pharmaceutical Sciences
researchProduct

Structure–activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of RO…

2007

ROCK has been implicated in many diseases ranging from glaucoma to spinal cord injury and is therefore an important target for therapeutic intervention. In this study, we have designed a series of 1-(4-(1H-indazol-5-yl)piperazin-1-yl)-2-hydroxy(or 2-amino) analogs and a series of 1-(4-(1H-indazol-5-yl amino)piperidin-1-yl)-2-hydroxy(or 2-amino) inhibitors of ROCK-II. SR-1459 has IC50 = 13 nM versus ROCK-II while the IC50s for SR-715 and SR-899 are 80 nM and 100 nM, respectively. Many of these inhibitors, especially the 2-amino substituted analogs for both series, are modest/potent CYP3A4 inhibitors as well. However, a few of these inhibitors (SR-715 and SR-899) show strong selectivity for R…

KinaseIndazolesInhibitorStereochemistryClinical BiochemistryPharmaceutical ScienceProtein Serine-Threonine KinasesPharmacologyBiochemistryPiperazinesInhibitory Concentration 50Structure-Activity Relationshipchemistry.chemical_compoundDrug StabilityPiperidinesIn vivoDrug DiscoveryAnimalsCytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsHumansStructure–activity relationshipPharmacokineticsRho-kinaseProtein Kinase InhibitorsMolecular BiologyCytochrome P-450 Enzyme Inhibitorsrho-Associated KinasesIndazoleCYP3A4Organic ChemistryIntracellular Signaling Peptides and ProteinsROCK-IIRatsPiperazinePharmaceutical PreparationschemistryMolecular MedicinePiperidineDrug metabolismBioorganic & Medicinal Chemistry Letters : a tetrahedron publication for the rapid dissemination of preliminary communication and all aspects of bioorganic chemistry, medicinal chemistry and related disciplines
researchProduct

Evidence of competitive inhibition of methotrexate absorption by leucovorin calcium in rat small intestine

1997

Abstract The effect of leucovorin calcium on the intestinal absorption of methotrexate in rat small intestine was investigated using an in situ rat gut technique. First, the kinetic absorption in situ parameters for methotrexate in solution were obtained: V m =21.54 (±2.22) μ M/h; K m =10.51 (±1.08) μ M; k a =0.26 (±0.03) h −1 and AIC=−188.63. The inhibitory effect of leucovorin calcium in methotrexate intestinal absorption has been investigated by perfusing of 10 μ M methotrexate isotonic solutions containing increasing concentrations of leucovorin calcium (10–500 μ M), and the remaining concentrations of both compounds were measured. A competitive inhibition of methotrexate absorption was…

Leucovorin CalciumChemistryReabsorptionPharmaceutical SciencePharmacologyIntestinal absorptionSmall intestineExcretionNon-competitive inhibitionmedicine.anatomical_structurePharmacokineticsmedicineMethotrexatemedicine.drugInternational Journal of Pharmaceutics
researchProduct

Simultaneous determination of levodopa methyl ester, levodopa, 3-O-methyldopa and dopamine in plasma by high-performance liquid chromatography with e…

1994

A new procedure is described for the simultaneous determination of levodopa methyl ester (LDME) and its biotransformation products levodopa (L-DOPA), 3-O-methyldopa (3-OMD) and dopamine (DA) in stabilized plasma samples, using reversed-phase high-performance liquid chromatography. A coulometric detector equipped with a dual-electrode system operating in the redox mode was used to simultaneously quantitate all compounds. This system generated a double signal monitored by a dual-channel acquisition data system and allowed quantitation of compounds at the nanogram level. The intra- and inter-assay precision varied in the 2.4-6.9% and 3.2-9.1% ranges respectively, whereas the recoveries were cl…

LevodopaChromatographyChemistryMetaboliteDopamineGeneral ChemistryReversed-phase chromatographyHigh-performance liquid chromatographyRatsCoulometryLevodopachemistry.chemical_compoundPharmacokineticsmedicineElectrochemistryAnimalsHumansTyrosine3-O-MethyldopaQuantitative analysis (chemistry)Oxidation-ReductionChromatography High Pressure Liquidmedicine.drugJournal of chromatography. B, Biomedical applications
researchProduct

Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.

2013

International audience; BACKGROUND: Lipids A, the lipophilic partial structure of lipopolysaccharides, induce regression of several tumor types in animal models. Rather than exerting direct cytotoxic effect, these compounds trigger the immune system which in turn stimulates secretion of cytokines, and activates the inducible nitric oxide synthase, as well as immune cell infiltration of tumors. OM-174 is an analogue of lipid A with dual action on toll-like receptors 2 and 4. In an experimental model of peritoneal carcinomatosis induced in BDIX rats by intraperitoneal injection of syngeneic PROb colon cancer cells, it induced a complete regression of tumors. The present phase I trial was cond…

LipopolysaccharidesMaleCancer Researchmedicine.medical_treatmentPharmacologyRefractory solid tumors[ SDV.CAN ] Life Sciences [q-bio]/CancerOM-1740302 clinical medicineNeoplasmsLipid A analogue0303 health sciencesMiddle Aged3. Good healthKiller Cells NaturalTreatment OutcomeCytokineOncology030220 oncology & carcinogenesisVomitingCytokinesFemaleChillsmedicine.symptomResearch ArticleAdultMaximum Tolerated DoseDoseIntraperitoneal injectionAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/CancerDrug Administration Schedule03 medical and health sciencesImmune systemPhase IPharmacokinetics[SDV.CAN] Life Sciences [q-bio]/CancerCell Line TumormedicineGeneticsAnimalsHumansImmune responseAged030304 developmental biologyChemotherapyPolymorphism Geneticbusiness.industryRatsToll-Like Receptor 4Disease Models Animalbusiness
researchProduct

Validation of a semi-physiological model for caffeine in healthy subjects and cirrhotic patients.

2015

The objective of this paper was to validate a previously developed semi physiological model to simulate bioequivalence trials of drug products. The aim of the model was to ascertain whether the measurement of the metabolite concentration-time profiles would provide any additional information in bioequivalence studies (Fernandez-Teruel et al., 2009a,b; Navarro-Fontestad et al., 2010). The semi-physiological model implemented in NONMEM VI was used to simulate caffeine and its main metabolite plasma levels using caffeine parameters from bibliography. Data from 3 bioequivalence studies in healthy subjects at 3 different doses (100, 175 and 400mg of caffeine) and one study in cirrhotic patients …

Liver CirrhosisMetabolitePopulationPharmaceutical ScienceBioequivalencePharmacologyModels BiologicalIntestinal absorptionchemistry.chemical_compoundPharmacokineticsCaffeineMedicineHumansComputer SimulationeducationBiotransformationParaxanthineeducation.field_of_studyDose-Response Relationship Drugbusiness.industryReproducibility of ResultsHealthy VolunteersNONMEMchemistryIntestinal AbsorptionTherapeutic EquivalencyCentral Nervous System StimulantsCaffeinebusinessAlgorithmsEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma : Final …

2016

Purpose Blinatumomab is a CD19/CD3 BiTE (bispecific T-cell engager) antibody construct for the treatment of Philadelphia chromosome–negative acute B-lymphoblastic leukemia. We evaluated blinatumomab in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Patients and Methods This 3 + 3 design, phase I dose-escalation study determined adverse events and the maximum tolerated dose (MTD) of continuous intravenous infusion blinatumomab in patients with relapsed/refractory NHL. Blinatumomab was administered over 4 or 8 weeks at seven different dose levels (0.5 to 90 μg/m2/day). End points were incidence of adverse events, pharmacokinetics, pharmacodynamics, and overall response rate. Results B…

Male0301 basic medicineOncologyCancer ResearchCD3 ComplexT-Lymphocytesmedicine.medical_treatmentMedizinLymphoma Mantle-CellLymphocyte Activation0302 clinical medicineRecurrenceGermanyhemic and lymphatic diseasesAntibodies BispecificMedicineMolecular Targeted TherapyInfusions IntravenousLymphoma FollicularLymphoma Non-HodgkinRemission InductionMiddle AgedLeukemiaTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleBlinatumomabImmunotherapymedicine.drugAdultmedicine.medical_specialtyLymphoma B-CellMaximum Tolerated DoseAntigens CD19Antineoplastic AgentsDrug Administration Schedule03 medical and health sciencesPharmacokineticsRefractoryInternal medicineHumansAdverse effectbusiness.industryImmunotherapymedicine.diseaseLymphomaSurgery030104 developmental biologyPharmacodynamicsNervous System Diseasesbusiness
researchProduct